Recombinant human erythropoietin is an efficacious therapy in treatment of the anemia of end-stage renal failure. However, the scale of impact on quality of life and medical care resources remains uncertain. By reviewing the literature we evaluate cost-effectiveness of recombinant human erythropoietin and show how previous studies may have implicitly overestimated cost-effectiveness.
|Number of pages||15|
|Journal||International Journal of Technology Assessment in Health Care|
|Publication status||Published - 1993|
Bibliographical noteFunding Information:
The authors acknowledge the financial support of the Dutch Health Council. We also thank Anton van Boxtel of the Health Council for his help in providing us with data from a survey conducted by Dialyse Groep Nederland.